HowShorted

How shorted is IDEAYA Biosciences, Inc.?

More shorted than 82% of the 2,877 ranked US companies

10.48%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
−0.42
5 reports (~10 weeks)
−2.84
Aggregate net short position time series for IDEAYA Biosciences, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202610.48%−0.42
15 Jul 202610.90%−0.86
30 Jun 202611.76%−0.34
15 Jun 202612.10%−0.80
29 May 202612.90%−0.42
15 May 202613.32%−0.01
30 Apr 202613.33%+1.30
15 Apr 202612.03%+0.91
31 Mar 202611.12%+0.05
13 Mar 202611.07%−0.01
27 Feb 202611.08%−0.30
13 Feb 202611.38%+0.75
30 Jan 202610.63%+0.70
15 Jan 20269.93%+0.52
31 Dec 20259.41%+1.17
15 Dec 20258.24%−0.56
28 Nov 20258.80%−0.36
14 Nov 20259.16%+0.19
31 Oct 20258.97%−0.71
15 Oct 20259.68%+0.10
30 Sep 20259.58%−1.21
15 Sep 202510.79%−0.72
29 Aug 202511.51%+0.50
15 Aug 202511.01%−0.55
31 Jul 202511.56%–

Frequently asked questions

How shorted is IDEAYA Biosciences, Inc. right now?
10.48% of IDEAYA Biosciences, Inc.'s (IDYA) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.